The Patent Finder

Terms ending in 2042

AbbVie Inc.

Every in-force patent on AbbVie Inc.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,433,951Methods of Treatment of Non-Small-Cell Lung Carcinoma Using Telisotuzumab Vedotin
In force
 · High confidence
AbbVie Manufacturing Management Unlimited CompanyIn forceHigh confidence
US 11,633,497Anti-C-Met Antibody Drug Conjugates
In force
 · High confidence
AbbVie Manufacturing Management Unlimited CompanyIn forceHigh confidence
US 11,759,527Anti-EGFR Antibody-Drug Conjugates
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
US 11,639,393ANTI-CCR8 Antibodies
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
US 11,767,310Nicotinamide RIPK1 Inhibitors
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
US 11,802,149Anti-Amyloid Beta Antibodies and Methods of Using the Same
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
6 of 6 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by AbbVie Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited